European studies of interleukin-2 in metastatic renal cell carcinoma.
Atzpodien
J
J
Division of Hematology/Oncology, Medizinische Hochschule Hannover, Germany.
Kirchner
H
H
Hänninen
E L
EL
Körfer
A
A
Fenner
M
M
Menzel
T
T
Deckert
M
M
Franzke
A
A
Jonas
U
U
Poliwoda
H
H
D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin; D005472:Fluorouracil